EUVIMEDEUVIMED entdecken
Open Access

CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche

Lynn Roy, Alexander Bobbs, Rachel Sattler, Jeffrey L Kurkewich, Paige B Dausinas, Prakash Nallathamby, Karen D Cowden Dahl

Cancer Growth and Metastasis · 2018

DOI: 10.1177/1179064418767882 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Growth and Metastasis, 2018. Verfasst von Lynn Roy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Harper Cancer Research Institute, South Bend, IN, USA. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer stem cells (CSCs) are an attractive therapeutic target due to their predicted role in both metastasis and chemoresistance. One of the most commonly agreed on markers for ovarian CSCs is the cell surface protein CD133. CD133+ ovarian CSCs have increased tumorigenicity, resistance to chemotherapy, and increased metastasis. Therefore, we were interested in defining how CD133 is regulated and whether it has a role in tumor metastasis. Previously we found that overexpression of the transcription factor, ARID3B, increased the expression of PROM1 (CD133 gene) in ovarian cancer cells in vitro and in xenograft tumors. We report that ARID3B directly regulates PROM1 expression. Importantly, in a xenograft mouse model of ovarian cancer, knockdown of PROM1 in cells expressing exogenous ARID3B resulted in increased survival time compared with cells expressing ARID3B and a control short hairpin RNA. This indicated that ARID3B regulation of PROM1 is critical for tumor growth. Moreover, we hypothesized that CD133 may affect metastatic spread. Given that the peritoneal mesothelium is a major site of ovarian cancer metastasis, we explored the role of PROM1 in mesothelial attachment. PROM1 expression increased adhesion to mesothelium in vitro and ex vivo. Collectively, our work demonstrates that ARID3B regulates PROM1 adhesion to the ovarian cancer metastatic niche.

Schlagwörter

Stichwörter der Autor:innen

Ovarian canceradhesioncancer stem cellsmetastasistranscription factor

Autor:innen und Institutionen

  • Harper Cancer Research Institute, South Bend, IN, USA.
  • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-South Bend, South Bend, IN, USA.
  • Department of Chemistry & Biochemistry, University of Notre Dame, Notre Dame, IN, USA.
  • Department of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
  • Department of Aerospace and Mechanical Engineering, University of Notre Dame, Notre Dame, IN, USA.
  • Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN, USA.

Zitieren

APA

Roy, L., Bobbs, A., Sattler, R., Kurkewich, J. L., Dausinas, P. B., Nallathamby, P., & Cowden Dahl, K. D. (2018). CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche. Cancer Growth and Metastasis. https://doi.org/10.1177/1179064418767882

Vancouver

Roy L, Bobbs A, Sattler R, Kurkewich JL, Dausinas PB, Nallathamby P, et al. CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche. Cancer Growth and Metastasis. 2018. doi:10.1177/1179064418767882

BibTeX
@article{Roy2018,
  author = {Roy, Lynn and Bobbs, Alexander and Sattler, Rachel and Kurkewich, Jeffrey L and Dausinas, Paige B and Nallathamby, Prakash and Cowden Dahl, Karen D},
  title = {CD133 Promotes Adhesion to the Ovarian Cancer Metastatic Niche},
  journal = {Cancer Growth and Metastasis},
  year = {2018},
  doi = {10.1177/1179064418767882}
}
Kostenlos starten →